WE Online, Jakarta –
Since its founding 100 years ago, insulin innovation continues to be developed. Now, Novo Nordisk, as the world’s diabetes care provider, is bringing one of its newest innovations to Indonesia.
“Even though insulin has been around for the past 100 years, there are always challenges and patient needs that have not been met when doing insulin therapy. Patients require simpler therapeutic procedures. Currently 2-in-1 insulin co-formulation is one of the innovations that can meet the needs of patients and can help millions of diabetics in Indonesia, “said Ketut Suastika, Chair of the Indonesian Endocrinology Association (PERKENI), in a Media Discussion with Novo Nordisk: Experience. the Freedom with Co-formulation Insulin virtually, Thursday (25/2/202).
Diabetes is a major health problem in Indonesia, which is now one of the ten countries with the highest number of diabetics in the world and is expected to increase and there is a need for interventions to prevent and manage diabetes.
Ketut Suastika said that health experts have developed guidelines to prevent and manage the disease. PERKENI has determined that a patient’s HbA1c level should reach 7%. Unfortunately, more than 70% of diabetic patients in Indonesia do not meet this target due to complex procedures.
“Patients undergoing insulin therapy usually need more than one injection of insulin per day to maintain blood sugar properly. Complex therapeutic procedures can decrease patient adherence rates and result in failure to lower targeted HbA1c levels. Therefore the presence of 2-in-1 insulin co-formulation IDegAsp gives new hope with a procedure that is simpler for patients to undergo. “
Ketut Suastika said that IDegAsp is the first and only 2-in-1 insulin co-formulation in the world that contains a new generation of basal degludec insulin and aspart insulin in one injection. The innovative 2-in-1 insulin co-formulation IDegAsp is designed to simplify insulin therapy so that it is easier to live, with only one injection a day and requires no re-suspension. This innovation is also safe because it has a low risk of hypoglycemia and has been shown to lower HbA1c levels and control blood sugar after meals. The 2-in-1 insulin co-formulation IDegAsp is an easier option for insulin therapy.
Vice President & General Manager of Novo Nordisk Indonesia, Anand Shetty said, “There are more than 10.7 million people with diabetes in Indonesia and this figure is expected to reach 16.6 million by 2045. As a form of our commitment to changing diabetes in Indonesia, Novo Nordisk has launched several initiatives over the years. By presenting IDegAsp 2-in-1 insulin co-formulation, we are bringing one of the latest insulin therapy innovations and expanding access to diabetes care for the public is a significant step in our efforts to improve adherence to diabetes patients while on insulin therapy. “
Managing diabetes with proper and stable glycemic control will prevent short- and long-term complications of diabetes and provide significant clinical and economic benefits.